Quan M, Cho N, Bushell T, Mak J, Nguyen N, Litwak J, Rockwood N, Nguyen HB. Effectiveness of angiotensin II for catecholamine refractory septic or distributive shock on mortality: a propensity core weighted analysis of real-world experience in the medical ICU. Crit Care Explor. 2022 Jan 18;4(1):e0623. doi: 10.1097/CCE.0000000000000623
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Willett W, Greenland S, MacMahon B, Trichopoulos D, Rothman KJ, Thomas D. The discipline of epidemiology. Science. 1995 Sep 8;269(5229):1325-6. doi: 10.1126/science.7660105
Rothman KJ. Journal policies on conflict of interest. Science. 1993 Sep 24;261(5129):1661. doi: 10.1126/science.8378766